Lake Street analyst Thomas Flaten has maintained their bullish stance on BDSX stock, giving a Buy rating today.
Thomas Flaten has given his Buy rating due to a combination of factors including Biodesix’s recent financial performance and future projections. The company reported a final revenue of $20.4 million for the fourth quarter of 2024, which exceeded previous estimates. Additionally, Biodesix has provided a revenue guidance for 2025 between $92 million and $95 million, indicating a positive growth trajectory.
Another critical factor in Flaten’s rating is the company’s expectation to achieve AEBITDA positivity in the second half of 2025 and reach cash flow breakeven with its current cash reserves. This financial stability reduces the likelihood of needing a near-term capital raise, which is a positive sign for investors. Despite recent share price pressures, Flaten believes that Biodesix’s fundamentals remain strong, with no significant competition and a large market opportunity, making it a promising long-term investment.
Flaten covers the Healthcare sector, focusing on stocks such as Personalis, Castle Biosciences, and Aquestive Therapeutics. According to TipRanks, Flaten has an average return of -8.7% and a 29.79% success rate on recommended stocks.